86P Efficacy and safety of IBI110 (anti-LAG-3 mAb) in combination with sintilimab (anti-PD-1 mAb) in advanced squamous non-small cell lung cancer (sqNSCLC): Updated results of the phase Ib study. (December 2022) - Zhou, C.; Xu, N.; A. Xiong,; Li, W.; Wang, L.; Wu, F.; Yu, J.; Mao, C.; Qian, J.; Zheng, Y.; Jiang, H.; Gao, Y.; et al.